

F41

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (previously presented): A method for treating an occult choroidal neovascular (CNV) lesion in a subject comprising providing photodynamic therapy (PDT) to a subject assessed as having either or both of (a) a small lesion with a size less than about 4-5 disc areas or (b) poor visual acuity of less than about 65 letters prior to treatment.
2. (original): The method of claim 1 wherein said subject was assessed by determining the size of said lesion and/or determining the best corrected visual acuity of the subject.
- 3-4. (canceled)
5. (original): The method of claim 1 wherein the small lesion has a size less than about 4 disc areas.
6. (original): The method of claim 1, wherein the occult CNV is in a subject afflicted or diagnosed with age-related macular degeneration (AMD).
7. (original): The method of claim 1 wherein said PDT comprises the administration of a photosensitizer (PS).
8. (original): The method of claim 7, wherein the PS is administered at a concentration ranging between about 2 to 8 mg/m<sup>2</sup> (PS/body surface area of subject).
9. (original): The method of claim 8, wherein the PS is administered at a concentration of 6 mg/m<sup>2</sup>.
10. (original): The method of claim 9, wherein the PS is a green porphyrin.

11. (original): The method of claim 10, wherein the green porphyrin is selected from BPD-DA, BPD-DB, BPD-MA, BPD-MB, EA6, and B3.
12. (original): The method of claim 11, wherein the green porphyrin is BPD-MA.
13. (original): The method of claim 10, wherein the PS is coupled to a specific binding ligand.
14. (original): The method of claim 7, wherein the PS is formulated with a carrier.
15. (original): The method of claim 14, wherein the formulation is selected from the group consisting of a liposome, emulsion, or aqueous solution.
16. (original): The method of claim 1, wherein said PDT comprises irradiation with electromagnetic radiation containing wavelengths in the visible light spectra.
17. (original): The method of claim 16, wherein the irradiation provides between  $12.5 \text{ J/cm}^2$  and  $100 \text{ J/cm}^2$ .
18. (original): The method of claim 17, wherein said irradiation occurs between 5 to 30 minutes after administration of a photosensitizer.
19. (original): The method of claim 7, wherein the PS is administered at a concentration ranging between about  $10 \text{ } \mu\text{g/kg}$  to  $100\text{mg/kg}$  (PS/body weight of subject).